Kayfanda (Odevixibat)

Odevixibat blocks the ileal bile acid transporter (ASBT) on the lining of the distal ileum. This inhibition prevents the normal recycling of bile acids from the intestine back to the liver, promoting their excretion in the stool. The resulting lower systemic bile acid levels alleviate the toxic buildup that characterises cholestatic liver diseases.

The specific dose of Kayfanda is individualized by the prescribing clinician based on the patient’s age, weight, disease severity, and laboratory results. Healthcare professionals determine the appropriate amount and frequency to achieve optimal therapeutic effect while minimizing potential adverse reactions.

Safety data for odevixibat in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To request Kayfanda, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Kayfanda’s mechanism—IBAT inhibition—differs from bile‑acid sequestrants or ursodeoxycholic acid, which aim to bind or replace bile acids. By directly reducing intestinal reabsorption, odevixibat offers a targeted approach that can achieve greater reductions in serum bile acids, particularly in genetic cholestasis such as PFIC2, where traditional therapies may be less effective.

Kayfanda should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in their original packaging, protect them from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout the shelf life.

Kayfanda is taken orally, usually as a tablet swallowed whole with water. The exact timing relative to meals may be guided by the prescribing physician, but it is generally recommended to follow the dosing schedule provided on the prescription label.

Serious risks include severe liver injury, cholestatic hepatitis, and rare allergic reactions that may present as rash, swelling, or breathing difficulties. Patients should be monitored regularly for liver enzyme elevations and any signs of hypersensitivity, and they should seek immediate medical attention if serious symptoms develop.

Kayfanda is contraindicated in patients with known hypersensitivity to odevixibat or any component of the formulation. It should also be avoided in individuals taking strong bile‑acid sequestrants or potent CYP3A4 inhibitors without medical supervision, as these interactions can significantly alter drug exposure.